Oltar (Glimepiride)

• Glimepiride is a sulfonylurea that targets pancreatic beta‑cell function to manage hyperglycaemia in type 2 diabetes mellitus.
• Type 2 diabetes mellitus: improves glycaemic control by increasing endogenous insulin secretion.
• Adjunct to diet and exercise: used when lifestyle measures alone do not achieve target glucose levels.
• Combination therapy with metformin: provides additional glucose‑lowering effect in patients requiring multi‑drug regimens.

• Glimepiride binds to the sulfonylurea receptor (SUR1) subunit of the ATP‑sensitive potassium channel on pancreatic beta cells. This binding closes the potassium channel, leading to cell depolarisation, calcium influx, and subsequent insulin granule exocytosis, thereby increasing circulating insulin levels and reducing blood glucose concentrations.

Glimepiride may cause a range of adverse reactions, from mild to severe. Awareness of potential side effects helps patients and clinicians monitor therapy safely.

Common Side Effects

• Hypoglycaemia: episodes of low blood sugar, especially when meals are missed.
• Weight gain: modest increase in body weight during treatment.
• Nausea or abdominal discomfort.
• Headache.
• Dizziness.
• Fatigue.

Serious or Rare Side Effects

• Severe hypoglycaemia requiring medical assistance.
• Allergic reactions such as rash, pruritus, or angio‑edema.
• Hematologic abnormalities (e.g., leukopenia, thrombocytopenia).
• Hepatic dysfunction presenting as jaundice or elevated liver enzymes.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Cardiovascular events in susceptible individuals.

Before initiating glimepiride therapy, several safety considerations should be reviewed.

• Monitor blood glucose: adjust dose to avoid hypoglycaemia.
• Assess renal function: dose may need modification in renal impairment.
• Evaluate hepatic status: use cautiously in liver disease.
• Caution in the elderly: increased sensitivity to hypoglycaemia.
• Avoid use in patients with known sulfonylurea hypersensitivity.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Glimepiride can interact with various medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Concomitant insulin or other sulfonylureas: risk of severe hypoglycaemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone): increase glimepiride plasma levels.
• Meglitinides: additive glucose‑lowering effect leading to hypoglycaemia.

Moderate Interactions (Monitor Closely)

• NSAIDs (e.g., ibuprofen): may potentiate hypoglycaemic effect.
• Beta‑blockers: can mask hypoglycaemia symptoms.
• Thiazide diuretics: may enhance hypoglycaemia.
• ACE inhibitors or ARBs: may affect renal handling of glucose.
• Alcohol: can potentiate hypoglycaemia, especially with missed meals.